32.67USD+0.28%Mkt Cap: 5.58B USDP/E: —Last update: 2026-05-22
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyros…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.58B USD
Enterprise Value5.01B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-328.94M USD
Revenue/Share—
Last Price32.67 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees258
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-34.65
PEG—
EV/EBITDA-13.92
EV/Revenue—
P/S—
P/B10.25
EPS (TTM)-2.17
EPS (Forward)-0.94
52W Range
4.75072% of range43.73
52W High43.73 USD
52W Low4.750 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-51.69%
ROA-35.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-264.44M USD
CapEx (TTM)1.55M USD
FCF Margin—
FCF Yield-3.00%
Net Debt-627.72M USD
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.38
Current Ratio15.14
Quick Ratio14.94
Book Value/Sh3.178 USD
Cash/Share5.069 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 9, 2020
Splits
Last Split1:4
Split DateNov 9, 2020
Analyst Consensus
Rating1.5 (Strong Buy)
Target (Mean)54.25 USD
Target Range35.00 USD – 72.00 USD
# Analysts12
Ownership
Shares Out.170.87M
Float160.86M
Insiders0.52%
Institutions112.14%
Short Interest
Short Ratio5.4d
Short % Float6.92%
Short % Out.6.88%
Shares Short11.75M
Short (prev mo.)17.43M
Technical
SMA 5035.46 (-7.9%)
SMA 20029.05 (+12.5%)
Beta0.37
S&P 52W Chg28.31%
Avg Vol (30d)1.67M
Avg Vol (10d)1.58M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—